GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status:
Withdrawn
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
Phase 1/2, open-label, dose-escalation study to assess the safety and tolerability of GCS-100
in combination with etoposide and dexamethasone in patients with relapsed or refractory
diffuse large B-cell lymphoma.